New endocrine agents

Cancer Treatment Reviews

Volumn 23, Issue SUPPL. 1, 1997, Pages

  Howell, Tony ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; DROLOXIFENE; ESTRADIOL; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; IDOXIFENE; LETROZOLE; MEGESTROL ACETATE; MESSENGER RNA; RALOXIFENE; TAMOXIFEN; TOREMIFENE; TRANSCRIPTION FACTOR; VOROZOLE;

ADVANCED CANCER; BODY WEIGHT DISORDER; BREAST CANCER; CLINICAL TRIAL; DRUG EFFICACY; ESTRADIOL BLOOD LEVEL; GENE ACTIVATION; HORMONAL THERAPY; HOT FLUSH; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; RECEPTOR BINDING; REVIEW; RNA TRANSCRIPTION; WEIGHT GAIN;

EID: 0030712134     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(97)90007-4     Document Type: Article

References (12)

1. Howell, A., Downey, S. & Anderson, E. (1996a) New endocrine therapies for breast cancer. Eur. J. Cancer 32A: 576-588.
2. Hayes, D. F., Van Zyl, J. A., Hacking, A., et al. (1995) Randomised comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J. Clin. Oncol. 13: 2556-2566.
3. Berry, M., Metzger, D. & Chambon, R (1990) Role for two activating domains of the oestrogen receptor in the cell type and promoter-context dependent agonist activity of the antioestrogen 4-hydroxytamoxifen. EMBO J. 9: 2811-2818.
4. Di Salle, E., Ornati, G., Paridaens, R., et al. (1994) Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304). In: Motta, M., Serio, M., eds. Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Amsterdam, The Netherlands: Elsevier, 303-309.
5. Howell, A., De Friend, D. J., Robertson, J. F. R., et al. (1996b) Pharmacokinetics, pharmacological and anti-tumour effects of the specific antioestrogen ICI 182780 in women with advanced breast cancer. Br. J. Cancer 74: 300-308.
6. Buzdar, A., Jonat, W., Howell, A., et al. (1996) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J. Clin. Oncol. 14: 200-2001.
7. Jonat, W., Buzdar, A., Howell, et al. (submitted for publication) Significantly improved survival with anastrozole versus megestrol acetate in postmenopausal women with advanced breast cancer: mature survival data from the overview analysis of two phase III trials.
8. Smith, I., Dombernowsky, P., Falkson, G., et al. (1996) Double-blind trial in postmenopausal women with advanced breast cancer showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate. Eur. J. Cancer 32A(Suppl 2): 49.
9. Marty, M., Gershanovich, M., Campos, B., et al. (1997) Letrozole, a new potent, selective aromatase inhibitor superior to aminoglutethimide in postmenopausal women with advanced breast cancer previously treated with antioestrogens. Proc. ASCO 16: 156a [Abstract 544].
10. Bergh, J., Bonneterre, J., Houston, S. J., et al. (1997) Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen. ASCO 1997 Abstract 543.
11. Goss, P., Winer, E., Tannock, I., Schwartz, L H. & Kremer, A.B. for the North American Vorozole Study Group. (1997) Vorozole vs. megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen. ASCO 1997 Abstract 542.
12. Sato, M., Glasebrook, A. L. & Bryant, H. U. (1994) Raloxifene: a selective oestrogen receptor modulator. J. Bone Miner. Met. 12(Suppl 2): S9-S20.